Rapcabtagene autoleucel
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| Other names | YTB323 |
| Routes of administration | Intravenous infusion |
| Drug class | CAR-T cell therapy |
| Legal status | |
| Legal status | |
| Identifiers | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
Rapcabtagene autoleucel (also known as YTB323) is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of relapsed or refractory B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL).[1] This next-generation CAR-T therapy is distinguished by its preserved T-cell stemness and rapid manufacturing process, which takes less than two days.[2]
Rapcabtagene autoleucel is an autologous CD19-directed CAR-T cell therapy that targets the CD19 antigen expressed on B-cell malignancies.[3] The therapy is engineered to preserve T-cell stemness, which is believed to contribute to enhanced CAR-T cell efficacy and persistence compared to traditional CAR-T therapies.[2] The manufacturing process is significantly shorter than conventional CAR-T therapies, requiring less than 48 hours from collection to final product, which may reduce the risk of disease progression during manufacturing delays.[2]
Clinical development
Phase I studies
The first-in-human phase I dose-escalation study of rapcabtagene autoleucel was conducted in patients with relapsed or refractory diffuse large B-cell lymphoma.[4][5] The study evaluated multiple dose levels, with dose level 2 (DL2) involving 12.5×10⁶ CAR+ viable T cells becoming the recommended dose for further studies.[3] At DL2, the complete response (CR) rate was 65%, with responses demonstrating durability over time.[4] When excluding patients who were already in complete response before receiving rapcabtagene autoleucel due to late effects of prior treatment or bridging chemotherapy, the CR rate at DL2 was 61%.[4]
The durability of responses was particularly notable, with CR rates maintained at 63% (12/19) at 3 months and 69% (11/16) at 6 months following treatment. This demonstrated the potential for long-lasting therapeutic benefit with rapcabtagene autoleucel treatment.[4]
Phase II studies
Building upon the promising Phase I results, a Phase II trial was initiated to further evaluate the efficacy and safety of rapcabtagene autoleucel in patients with relapsed or refractory DLBCL.[6][5] Interim analysis results presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed promising efficacy outcomes.[7]
In the Phase II trial, patients treated with rapcabtagene autoleucel (n = 63) achieved an overall response rate (ORR) of 88.3% (95% CI, 77.4%-95.2%).[7] The complete response rate was 65.0%, consistent with the Phase I findings.[7] When patients who were already in complete response prior to treatment were excluded (n = 4), the CR rate was 62.5%.[8]
Clinical efficacy
The clinical efficacy of rapcabtagene autoleucel has been demonstrated through multiple studies showing consistent response rates and durability of responses in heavily pretreated patients with relapsed or refractory DLBCL.[9] At a median follow-up of 16 months in the Phase II study, rapcabtagene autoleucel was associated with a complete response rate of 65%, with durable responses observed in 54% of responders still maintaining their response at the 12-month timepoint.[8][5]
The therapy has demonstrated activity at significantly lower doses than traditionally required for CAR-T therapies, which may contribute to its favorable safety profile while maintaining efficacy.[2]
Safety profile
Clinical studies have reported that rapcabtagene autoleucel demonstrates a manageable safety profile in patients with relapsed or refractory DLBCL.[4] The Phase II trial data continued to support the use of the lower-dose lymphodepletion (LD) regimen before infusion, with risk-benefit analysis favoring this approach.[6]
Manufacturing and administration
One of the distinguishing features of rapcabtagene autoleucel is its rapid manufacturing process, which requires less than 2 days from T-cell collection to final product release.[2] This abbreviated manufacturing timeline is significantly shorter than conventional CAR-T therapies, which typically require 2–4 weeks for production. The shorter manufacturing time reduces the risk of disease progression during the waiting period and may allow for treatment of patients with rapidly progressive disease who might otherwise not be candidates for CAR-T therapy.
The recommended dose for clinical use is 12.5×10⁶ CAR+ viable T cells (DL2), which was established through dose-escalation studies and confirmed in Phase II trials.[3] This dose level has consistently demonstrated optimal efficacy while maintaining an acceptable safety profile across multiple studies.